MK PHARMA LIMITED

Company Registration Number:
08737318 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2023

Period of accounts

Start date: 01 January 2023

End date: 31 December 2023

MK PHARMA LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2023

Balance sheet
Notes

MK PHARMA LIMITED

Balance sheet

As at 31 December 2023


Notes

2023

2022


£

£
Fixed assets
Intangible assets: 3 1,750,000 1,765,000
Tangible assets: 4 356,777 366,563
Total fixed assets: 2,106,777 2,131,563
Current assets
Stocks: 29,132 32,820
Debtors:   230,442 213,350
Cash at bank and in hand: 159,076 94,261
Total current assets: 418,650 340,431
Creditors: amounts falling due within one year: 5 (732,076) (618,518)
Net current assets (liabilities): (313,426) (278,087)
Total assets less current liabilities: 1,793,351 1,853,476
Creditors: amounts falling due after more than one year: 6 (948,456) (1,039,130)
Total net assets (liabilities): 844,895 814,346
Capital and reserves
Called up share capital: 100 100
Revaluation reserve:7525,000525,000
Other reserves: 35,000 35,000
Profit and loss account: 284,795 254,246
Shareholders funds: 844,895 814,346

The notes form part of these financial statements

MK PHARMA LIMITED

Balance sheet statements

For the year ending 31 December 2023 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 27 September 2024
and signed on behalf of the board by:

Name: Idris Karimjee
Status: Director

The notes form part of these financial statements

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

2. Employees

2023 2022
Average number of employees during the period 12 12

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

3. Intangible Assets

Total
Cost £
At 01 January 2023 1,900,000
At 31 December 2023 1,900,000
Amortisation
At 01 January 2023 135,000
Charge for year 15,000
At 31 December 2023 150,000
Net book value
At 31 December 2023 1,750,000
At 31 December 2022 1,765,000

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

4. Tangible Assets

Total
Cost £
At 01 January 2023 465,187
At 31 December 2023 465,187
Depreciation
At 01 January 2023 98,624
Charge for year 9,786
At 31 December 2023 108,410
Net book value
At 31 December 2023 356,777
At 31 December 2022 366,563

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

5. Creditors: amounts falling due within one year note

Total as at 31.12.2023 - £732,076 Total as at 31.12.2022 - £618,518

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

6. Creditors: amounts falling due after more than one year note

Total as at 31.12.2023 - £948,456 Total as at 31.12.2022 - 1,039,130

MK PHARMA LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2023

7. Revaluation reserve

2023
£
Balance at 01 January 2023 525,000
Surplus or deficit after revaluation 0
Balance at 31 December 2023 525,000